Hybrid And Complex Opportunities Remain At The Heart Of Endo’s Strategy
Endo continues to see value in 505(b)(2) sterile injectables and complex generics, while “swift, tough decisions” on its more commoditised US retail generics are helping put the company ahead of its competitors.
You may also be interested in...
Endo’s Par has announced the first launch under a longstanding US collaboration with 505(b)(2) specialist Nevakar, in the form of pre-mixed ephedrine sulfate injection in a ready-to-use 50mg/10ml single-use vial.
Endo has announced that it will not pursue a previously-announced US$190 million deal to augment its injectables portfolio and pipeline by acquiring Somerset Therapeutics and its India-based Wintac contract development and manufacturing business. The news comes as Endo has reported US generics sales down by a third – and total turnover down by 15% – in 2018.
In an acquisition said by both US-based companies to be highly complementary, Azurity Pharmaceuticals has taken control of Slayback Pharma for an undisclosed fee.